111 related articles for article (PubMed ID: 25564305)
1. Shared structural features of the 9aaTAD family in complex with CBP.
Piskacek M; Vasku A; Hajek R; Knight A
Mol Biosyst; 2015 Mar; 11(3):844-51. PubMed ID: 25564305
[TBL] [Abstract][Full Text] [Related]
2. Universal two-point interaction of mediator KIX with 9aaTAD activation domains.
Hofrova A; Lousa P; Kubickova M; Hritz J; Otasevic T; Repko M; Knight A; Piskacek M
J Cell Biochem; 2021 Oct; 122(10):1544-1555. PubMed ID: 34224597
[TBL] [Abstract][Full Text] [Related]
3. Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP.
Lee CW; Arai M; Martinez-Yamout MA; Dyson HJ; Wright PE
Biochemistry; 2009 Mar; 48(10):2115-24. PubMed ID: 19220000
[TBL] [Abstract][Full Text] [Related]
4. The NFkB activation domain is 14-amino-acid-long variant of the 9aaTAD.
Houser J; Jendruchova K; Knight A; Piskacek M
Biochem J; 2023 May; 480(5):297-306. PubMed ID: 36825663
[TBL] [Abstract][Full Text] [Related]
5. Structural and mechanistic insights into the interaction of the circadian transcription factor BMAL1 with the KIX domain of the CREB-binding protein.
Garg A; Orru R; Ye W; Distler U; Chojnacki JE; Köhn M; Tenzer S; Sönnichsen C; Wolf E
J Biol Chem; 2019 Nov; 294(45):16604-16619. PubMed ID: 31515273
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for cooperative transcription factor binding to the CBP coactivator.
De Guzman RN; Goto NK; Dyson HJ; Wright PE
J Mol Biol; 2006 Feb; 355(5):1005-13. PubMed ID: 16253272
[TBL] [Abstract][Full Text] [Related]
7. Critical role for a single leucine residue in leukemia induction by E2A-PBX1.
Bayly R; Murase T; Hyndman BD; Savage R; Nurmohamed S; Munro K; Casselman R; Smith SP; LeBrun DP
Mol Cell Biol; 2006 Sep; 26(17):6442-52. PubMed ID: 16914730
[TBL] [Abstract][Full Text] [Related]
8. Leu628 of the KIX domain of CBP is a key residue for the interaction with the MLL transactivation domain.
Arai M; Dyson HJ; Wright PE
FEBS Lett; 2010 Nov; 584(22):4500-4. PubMed ID: 20969867
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into TAZ2 domain-mediated CBP/p300 recruitment by transactivation domain 1 of the lymphopoietic transcription factor E2A.
Lochhead MR; Brown AD; Kirlin AC; Chitayat S; Munro K; Findlay JE; Baillie GS; LeBrun DP; Langelaan DN; Smith SP
J Biol Chem; 2020 Mar; 295(13):4303-4315. PubMed ID: 32098872
[TBL] [Abstract][Full Text] [Related]
10. The 9aaTAD Is Exclusive Activation Domain in Gal4.
Piskacek M; Havelka M; Rezacova M; Knight A
PLoS One; 2017; 12(1):e0169261. PubMed ID: 28056036
[TBL] [Abstract][Full Text] [Related]
11. Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain.
Goto NK; Zor T; Martinez-Yamout M; Dyson HJ; Wright PE
J Biol Chem; 2002 Nov; 277(45):43168-74. PubMed ID: 12205094
[TBL] [Abstract][Full Text] [Related]
12. The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with valines and intron reservoirs.
Piskacek M; Havelka M; Jendruchova K; Knight A; Keegan LP
Cell Mol Life Sci; 2020 May; 77(9):1793-1810. PubMed ID: 31375868
[TBL] [Abstract][Full Text] [Related]
13. Conformational control of the binding of the transactivation domain of the MLL protein and c-Myb to the KIX domain of CREB.
Korkmaz EN; Nussinov R; Haliloğlu T
PLoS Comput Biol; 2012; 8(3):e1002420. PubMed ID: 22438798
[TBL] [Abstract][Full Text] [Related]
14. Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment.
Wang F; Marshall CB; Yamamoto K; Li GY; Gasmi-Seabrook GM; Okada H; Mak TW; Ikura M
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6078-83. PubMed ID: 22474372
[TBL] [Abstract][Full Text] [Related]
15. The 9aaTAD Transactivation Domains: From Gal4 to p53.
Piskacek M; Havelka M; Rezacova M; Knight A
PLoS One; 2016; 11(9):e0162842. PubMed ID: 27618436
[TBL] [Abstract][Full Text] [Related]
16. Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2.
Ferreon JC; Lee CW; Arai M; Martinez-Yamout MA; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6591-6. PubMed ID: 19357310
[TBL] [Abstract][Full Text] [Related]
17. Rational peptide design for inhibition of the KIX-MLL interaction.
Sato N; Suetaka S; Hayashi Y; Arai M
Sci Rep; 2023 Apr; 13(1):6330. PubMed ID: 37072438
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of CBP/p300 recruitment in leukemia induction by E2A-PBX1.
Denis CM; Chitayat S; Plevin MJ; Wang F; Thompson P; Liu S; Spencer HL; Ikura M; LeBrun DP; Smith SP
Blood; 2012 Nov; 120(19):3968-77. PubMed ID: 22972988
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the promiscuous interactions between intrinsically disordered transactivation domains and the KIX domain.
Huang Y; Gao M; Yang F; Zhang L; Su Z
Proteins; 2017 Nov; 85(11):2088-2095. PubMed ID: 28786199
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interplay between promoter recognition and CBP/p300 coactivator recruitment by FOXO3a.
Wang F; Marshall CB; Li GY; Yamamoto K; Mak TW; Ikura M
ACS Chem Biol; 2009 Dec; 4(12):1017-27. PubMed ID: 19821614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
